Recurrent uterine corpus carcinoma Trials in Providence, United States
Conditions / Recurrent uterine corpus carcinoma / Providence, United States
Recurrent uterine corpus carcinoma has been the subject of sustained clinical investigation across multiple research sites.
12 total trials for this combination
Showing top 10 of 12 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01225887 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00897442 | Collecting Tumor Samples From Patients With Gynecological Tumors | COMPLETED | — |
| NCT01642082 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT02065687 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | UNKNOWN | PHASE2/PHASE3 |
| NCT00729586 | Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01098630 | Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer | COMPLETED | — |
| NCT01132820 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | COMPLETED | PHASE2 |
| NCT00063999 | Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | COMPLETED | PHASE3 |